Replimune Group Inc (REPL) USD0.001

Sell:$10.96Buy:$10.97$0.20 (1.86%)

NASDAQ:0.22%
Market closed | Prices delayed by at least 15 minutes
Sell:$10.96
Buy:$10.97
Change:$0.20 (1.86%)
Market closed | Prices delayed by at least 15 minutes
Sell:$10.96
Buy:$10.97
Change:$0.20 (1.86%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Key people

Philip Astley-Sparke
Executive Chairman of the Board
Sushil Patel
Chief Executive Officer, Director
Emily Luisa Hill
Chief Financial Officer
Christopher Sarchi
Chief Commercial Officer
Konstantinos Xynos
Chief Medical Officer
Dieter Weinand
Lead Independent Director
Madhavan Balachandran
Director
Kapil Dhingra
Independent Director
Michael J. Goller
Independent Director
Christy J. Oliger
Independent Director
Click to see more

Key facts

  • EPIC
    REPL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US76029N1063
  • Market cap
    $800.93m
  • Employees
    479
  • Shares in issue
    77.09m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.